Aspen Neuroscience
PrivateLast Round
Series C
Nov 20, 2025
Total Funding Raised
$387M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Aspen Neuroscience operates in Healthcare & Life Sciences and is based in San Diego, California. Its latest recorded funding round was a Series C round in November 2025.
Aspen Neuroscience is a biotechnology company that develops autologous cell therapies and personalized medicines aimed at treating a wide range of diseases, beginning with Parkinson's disease, through the use of advanced genomic AI and pluripotent stem cell biology for patient-specific restorative treatments.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Precision Medicine, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Aspen Neuroscience Comparables
Compare Aspen Neuroscience with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Oryon Cell Therapies | 90% | |
| BrainXell Therapeutics | 87% | |
| Kenai Therapeutics | 87% |
For institutional investors. Book with your work email.
Aspen Neuroscience Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Nov 20, 2025 | ||||
| Grant | May 15, 2024 | ||||
| Debt | Dec 21, 2022 | ||||
| Series B | May 9, 2022 | ||||
| Series A | Apr 1, 2020 | ||||
Seed | Dec 12, 2019 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Aspen Neuroscience Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| S32 | Series B, Seed, Series C, Series A |
| Conrad Prebys Foundation | Series C |
| Balyasny Asset Management L.P. | Series C |
| Prebys Ventures | Series C |
| Frazier Healthcare Partners | Series A |
| GV | Series B |
| Cormorant Asset Management | Series C |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 18, 2026
New 12-month data released from ASPIRO trial of sasineprocel.
- Mar 18, 2026
Presented at the AD/PD 2026 International Conference in March 2026.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingOct 26, 2026
Aspen Neuroscience, Inc. is developing therapies for neurodegenerative diseases in California, with its lead product candidate, sasineprocel, in an early-to-mid-stage trial for Parkinson’s disease.
For institutional investors. Book with your work email.
Aspen Neuroscience Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Aspen Neuroscience's valuation, stock price, and market status.
Is Aspen Neuroscience a public or private company?
Aspen Neuroscience is a private company.
What is the current stock price of Aspen Neuroscience?
Aspen Neuroscience is a private company, so its shares have no public market price. Caplight tracks Aspen Neuroscience's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Aspen Neuroscience worth (valuation)?
Valuation information for Aspen Neuroscience is not publicly available.
Can I buy Aspen Neuroscience stock?
Aspen Neuroscience shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Aspen Neuroscience's last funding round?
Aspen Neuroscience's most recent funding round was Series C on November 20, 2025.
Who are the main investors in Aspen Neuroscience?
Key investors in Aspen Neuroscience include GV, Domain Associates, LYFE Capital, OrbiMed, Frazier Life Sciences.
Will Aspen Neuroscience IPO soon?
No public IPO plans have been announced for Aspen Neuroscience.
How can I track Aspen Neuroscience secondary market activity?
Caplight tracks bids, offers, and trades in Aspen Neuroscience's shares on secondary markets.